fda bpc-157 compounding safety risks immunogenicity Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions Regeneration or Risk? A Narrative
Description
Mixing BPC-157 and TB-500 in a single injection syringe appears acceptable based on available evidence
It has been proven that BV inhibits proliferation and causes apoptotic cell death by activating death receptors (DR4 and DR5) (Khaliq et al., 2022)
Supporting this extended regeneration phase with compounds like BPC 157 peptide may result in more complete, resilient repairs that are less likely to re-injure
Like any injection, there may be some bruising, redness, and soreness at the injection site.
